Synonyms: QAX-576 | QAX576
Compound class:
Antibody
Comment: Dectrekumab is a fully human investigational anti-interleukin 13 (IL-13) monoclonal antibody, with anti-inflammatory potential.
Peptide sequence and secondary structural information are available from dectrekumab's IMGT/mAb-DB record. Peptide sequences for the heavy and light chains of dectrekumab match those provided in patent US8992916 B2 for clone 01951/G12 [1]. |
References |
1. Campbell EM, Parveen S, Buechler J, Valkirs G. (2015)
Methods of using anti-IL13 human antibodies. Patent number: US8992916 B2. Assignee: Novartis Ag.. Priority date: 21/10/2005. Publication date: 31/03/2015. |
2. Rothenberg ME, Wen T, Greenberg A, Alpan O, Enav B, Hirano I, Nadeau K, Kaiser S, Peters T, Perez A et al.. (2015)
Intravenous anti-IL-13 mAb QAX576 for the treatment of eosinophilic esophagitis. J Allergy Clin Immunol, 135 (2): 500-7. [PMID:25226850] |